Irisin and Fibroblast Growth Factor 21 (FGF-21) have been proposed as prognostic and/or diagnostic biomarkers in subjects with obesity and metabolic syndrome, because they increase earlier than other traditional biomarkers. This evidence concerns the gene FGF21 and obesity due to melanocortin 4 receptor deficiency.